US2010040539A1PendingUtilityA1

Vector System

73
Assignee: OXFORD BIOMEDICA LTDPriority: Nov 18, 1999Filed: May 15, 2008Published: Feb 18, 2010
Est. expiryNov 18, 2019(expired)· nominal 20-yr term from priority
Inventors:Alan KingsmanSusan KingsmanChristopher R. BebbingtonMiles CarrollFiona EllardKevin Myers
A61K 2039/505C07K 2317/732C07K 2319/00C07K 2317/52C07K 16/28C07K 2317/622C07K 16/30A61P 35/00C07K 16/1145
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.

Claims

exact text as granted — not AI-modified
1 - 24 . (canceled) 
     
     
         25 . An antibody having binding specificity for 5T4 antigen (5T4Ab) conjugated to any one or more of an antibody an isotope, an enzyme, a carrier protein, a cytotoxic drug, a fluorescent molecule and a radioactive nucleotide. 
     
     
         26 - 45 . (canceled) 
     
     
         46 . A method of preventing and/or treating a disease associated with 5T4 expression, comprising administering to a subject the antibody conjugate according to  claim 25 . 
     
     
         47 - 78 . (canceled) 
     
     
         79 . A pharmaceutical composition comprising the antibody conjugate of  claim 25 . 
     
     
         80 . The pharmaceutical composition of  claim 79  further comprising another therapeutic agent. 
     
     
         81 - 95 . (canceled) 
     
     
         96 . A conjugate comprising an antibody that binds to 5T4 antigen (5T4Ab) linked to a cytotoxic agent, wherein the 5T4Ab binds 5T4 on the surface of tumor cells expressing 5T4, and wherein the conjugate is capable of killing tumor cells to which it binds. 
     
     
         97 . The conjugate according to  claim 96 , wherein the 5T4Ab is a monoclonal antibody. 
     
     
         98 . The conjugate according to  claim 96 , wherein the 5T4Ab is a single chain antibody (scFv). 
     
     
         99 . The conjugate according to  claim 96 , wherein the 5T4Ab binds to human 5T4 antigen. 
     
     
         100 . The conjugate according to  claim 96 , wherein the 5T4Ab is a recombinant 5T4Ab. 
     
     
         101 . The conjugate according to  claim 96 , wherein the 5T4Ab is a chimeric 5T4Ab. 
     
     
         102 . The conjugate according to  claim 96 , wherein the 5T4Ab comprises 5T4 complementarity determining regions (CDRs) according SEQ ID NO: 1. 
     
     
         103 . The conjugate according to  claim 96 , wherein the cytotoxic agent is a protein toxin. 
     
     
         104 . The conjugate according to  claim 96 , wherein the cytotoxic agent is a cytotoxic drug. 
     
     
         105 . The conjugate according to  claim 96 , wherein the cytotoxic agent is a cytotoxic chemical agent. 
     
     
         106 . The conjugate according to  claim 96 , wherein the cytotoxic chemical agent is an intercalating agent. 
     
     
         107 . The conjugate according to  claim 96 , wherein the cytotoxic agent is a DNA damaging agent. 
     
     
         108 . A method for killing a 5T4-expressing cell comprising contacting the cell with an effective amount of a conjugate according to  claim 96 . 
     
     
         109 . The method according to  claim 108 , wherein the 5T4-expressing cell is cancer cell. 
     
     
         110 . The method according to  claim 109 , wherein the 5T4-expressing cell is a tumor cell. 
     
     
         111 . A method for treating cancer in a subject comprising administering to the subject a conjugate according to  claim 96 . 
     
     
         112 . The method according to  claim 111 , wherein the cancer is a solid tumor. 
     
     
         113 . The method according to  claim 111 , wherein the subject is a human. 
     
     
         114 . The antibody conjugate of  claim 25 , wherein the 5T4Ab is an ScFv antibody. 
     
     
         115 . The antibody conjugate of  claim 25 , wherein the 5T4Ab comprises 5T4 complementarity determining regions (CDRs) according to SEQ ID NO: 1. 
     
     
         116 . An antibody having binding specificity for 5T4 antigen (5T4Ab) linked to one or more antibodies having binding specificity for one or more disease associated molecules. 
     
     
         117 . The antibody of  claim 116 , wherein the 5T4Ab comprises 5T4 complementarity determining regions (CDRs) according to SEQ ID NO: 1. 
     
     
         118 . A 5T4 antibody (5T4Ab) having two or more binding sites, wherein at least one binding site is specific for 5T4 antigen. 
     
     
         119 . The antibody of  claim 118 , wherein the 5T4Ab comprises 5T4 complementarity determining regions (CDRs) according to SEQ ID NO: 1. 
     
     
         120 . A composition comprising an ScFv antibody which binds 5T4 antigen (5T4Ab), wherein the 5T4Ab is linked to another ScFv antibody. 
     
     
         121 . The composition of  claim 120 , wherein the 5T4Ab comprises 5T4 complementarity determining regions (CDRs) according to SEQ ID NO: 1.

Join the waitlist — get patent alerts

Track US2010040539A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.